Rhabdomyosarcoma staging: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(30 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Rhabdomyosarcoma}}
{{Rhabdomyosarcoma}}
{{CMG}}
{{CMG}};{{AE}} {{S.M}}
==Overview==
==Overview==
There are two [[Cancer staging|staging]] [[classification]] for [[rhabdomyosarcoma]] including Children group (CG) and [[tumor]], [[Node (physics)|node]], and [[metastasis]] system (TNM). Each of them has four stages of [[rhabdomyosarcoma]] based on the location of [[tumor]], size of [[tumor]], involvement of [[lymph nodes]], and [[metastasis]]. Also, [[Risk Stratification Tools|risk]] [[stratification]] [[system]] is used for [[classification]] of [[patients]] into low, intermediate, and high risk groups.
==Staging of rhabdomyosarcoma==
==Staging of rhabdomyosarcoma==
* There are two [[Cancer staging|staging]] [[classification]] for [[rhabdomyosarcoma]]:<ref name="pmid2407808">{{cite journal| author=Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B et al.| title=Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. | journal=J Clin Oncol | year= 1990 | volume= 8 | issue= 3 | pages= 443-52 | pmid=2407808 | doi=10.1200/JCO.1990.8.3.443 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2407808  }} </ref>
** Clinical group (CG)
*** Created by intergroup rhabdomyosarcoma study group (IRSG) in 1972.
*** Based on spread of [[tumor]] [[Cells (biology)|cells]] at [[diagnosis]] and remaining [[disease]] after [[surgery]].
*** Categorized in four groups.
** [[Tumor]], node, and [[metastasis]] [[system]] (TNM)
*** Based on [[tumor]] size, node involvement, and [[metastases]].
***Categorized in four groups.
{| class="wikitable"
|+Clinical group staging<ref name="pmid7884423">{{cite journal| author=Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C et al.| title=The Third Intergroup Rhabdomyosarcoma Study. | journal=J Clin Oncol | year= 1995 | volume= 13 | issue= 3 | pages= 610-30 | pmid=7884423 | doi=10.1200/JCO.1995.13.3.610 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7884423  }} </ref>
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Group
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Description
|-
| style="background:#DCDCDC;" align="center" + |I
| style="background:#F5F5F5;" + |
* Contain 13% of all cases
* Localized region
* Complete [[resection]]
* No nodal involvement
|-
| style="background:#DCDCDC;" align="center" + |II
| style="background:#F5F5F5;" + |
* Contain 20% of all cases
* IIA group: Complete [[resection]] with [[microscopic]] [[residual]] [[disease]]/ no nodal involvement
* IIB group: Complete [[resection]] with no [[microscopic]] [[residual]] [[Disease|diseases]]/ regional nodal involvement
* IIC group: Complete [[resection]] with [[microscopic]] [[residual]] [[disease]]/ regional nodal involvement
|-
| style="background:#DCDCDC;" align="center" + |III
| style="background:#F5F5F5;" + |
* Contain 48% of all cases
* Incomplete [[resection]] or [[biopsy]]
* [[Gross]] [[residual]] [[disease]]
|-
| style="background:#DCDCDC;" align="center" + |IV
| style="background:#F5F5F5;" + |
* Contain 18% of all cases
* Distant [[metastases]] at time of [[diagnosis]]
|}
{| class="wikitable"
|+TNM system<ref name="pmid11408506">{{cite journal| author=Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB et al.| title=Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. | journal=J Clin Oncol | year= 2001 | volume= 19 | issue= 12 | pages= 3091-102 | pmid=11408506 | doi=10.1200/JCO.2001.19.12.3091 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11408506  }}</ref><ref name="pmid27955730">{{cite journal| author=Dasgupta R, Fuchs J, Rodeberg D| title=Rhabdomyosarcoma. | journal=Semin Pediatr Surg | year= 2016 | volume= 25 | issue= 5 | pages= 276-283 | pmid=27955730 | doi=10.1053/j.sempedsurg.2016.09.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27955730  }} </ref>
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Stage
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Description
|-
| style="background:#DCDCDC;" align="center" + |1
| style="background:#F5F5F5;" + |
* Involvement of [[orbit]], [[head]] and [[neck]] (except parameningeal), [[genitourinary]] (non-[[bladder]], non-[[prostate]]), and [[biliary tract]].
* [[Tumor]] stage [[invasion]]: T1 ( Confined to [[anatomic]] site of origin) or T2 ( include [[extension]]).
* [[Tumor]] size: a ( ≤5 cm in [[diameter]]) or b ( >5 cm in [[diameter]]).
* Regional nodes: It varies from N0 ( not clinically involve), N1 (clinically involved) to Nx (clinical status unknown).
* [[Metastases]]: M0 (no [[metastases]]).
|-
| style="background:#DCDCDC;" align="center" + |2
| style="background:#F5F5F5;" + |
* Involvement of [[Bladder]], [[prostate]], [[extremities]], [[cranial]] parameningeal, and other sites ( [[trunk]], [[retroperitoneum]], etc, excluding [[biliary tract]]).
* [[Tumor]] stage [[invasion]]: T1 ( Confined to [[anatomic]] site of [[origin]]) or T2 ( include [[extension]]).
* [[Tumor]] size: a ( ≤5 cm in [[diameter]]).
* Regional nodes: N0  (not clinically involve) N1 (clinically involved).
* [[Metastases]]: M0 (no [[metastases]]).
|-
| style="background:#DCDCDC;" align="center" + |3
| style="background:#F5F5F5;" + |
* Involvement of [[bladder]], [[prostate]], [[extremities]], [[cranial]] parameningeal, and other sites ( [[trunk]], [[retroperitoneum]], etc, excluding [[biliary tract]]).
* Tumor stage [[invasion]]: T1 ( Confined to [[anatomic]] site of origin) or T2 ( include [[extension]]).
* [[Tumor]] size: a ( ≤5 cm in [[diameter]]) or b ( >5 cm in [[diameter]]).
* Regional nodes: When [[tumor]] size is a, regional node category would be N1 ( clinically involve); however, if the [[tumor]] size is b, regional node category  varies from N0 ( not clinically involve), N1 (clinically involved) to Nx (clinical status unknown).
* [[Metastases]]: M0 (no [[metastases]]).
|-
| style="background:#DCDCDC;" align="center" + |4
| style="background:#F5F5F5;" + |
* Involvement could be all sites.
* [[Tumor]] stage: T1 ( Confined to [[anatomic]] site of [[origin]]) or T2 ( include [[extension]]).
* [[Tumor]] size: a ( ≤5 cm in [[diameter]]) or b ( >5 cm in [[diameter]]).
* Regional nodes: N0  (not clinically involve) N1 (clinically involved).
* [[Metastases]]: Present distant [[metastases]].
|}
{| class="wikitable"
|+Risk classification<ref name="pmid11846299">{{cite journal| author=Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ et al.| title=Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. | journal=J Pediatr Hematol Oncol | year= 2001 | volume= 23 | issue= 4 | pages= 215-20 | pmid=11846299 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11846299  }}</ref>
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk type
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Description
|-
| style="background:#DCDCDC;" align="center" + |Low
| style="background:#F5F5F5;" + |
* [[Patients]] with [[embryonal rhabdomyosarcoma]] at a favorable sites ( stage 1).
* [[Patients]] with [[embryonal rhabdomyosarcoma]] at  an unfavorable sites with complete [[resection]] ( group I).
* [[Patients]] with [[embryonal rhabdomyosarcoma]] at an unfavorable site with [[microscopic]] [[residual]] [[disease]] (group II).
|-
| style="background:#DCDCDC;" align="center" + |Intermediate
| style="background:#F5F5F5;" + |
* [[Patients]] with [[embryonal rhabdomyosarcoma]] at an unfavorable site with [[gross]] [[residual]] [[disease]] (group III).
* [[Patients]] with [[metastatic]] [[embryonal rhabdomyosarcoma]] and [[age]] < 10 years.
* [[Patients]] with nonmetastatic [[alveolar rhabdomyosarcoma]].
|-
| style="background:#DCDCDC;" align="center" + |High
| style="background:#F5F5F5;" + |
* [[Patient]] with [[metastatic]] [[disease]] (excluding [[patients]] with [[metastatic]] [[embryonal rhabdomyosarcoma]] and [[age]] < 10 years).
|}


==References==
==References==
Line 12: Line 112:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Orthopedics]]

Latest revision as of 15:36, 8 March 2019

Rhabdomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rhabdomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rhabdomyosarcoma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rhabdomyosarcoma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rhabdomyosarcoma staging

CDC on Rhabdomyosarcoma staging

Rhabdomyosarcoma staging in the news

Blogs on Rhabdomyosarcoma staging

Directions to Hospitals Treating Rhabdomyosarcoma

Risk calculators and risk factors for Rhabdomyosarcoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]

Overview

There are two staging classification for rhabdomyosarcoma including Children group (CG) and tumor, node, and metastasis system (TNM). Each of them has four stages of rhabdomyosarcoma based on the location of tumor, size of tumor, involvement of lymph nodes, and metastasis. Also, risk stratification system is used for classification of patients into low, intermediate, and high risk groups.

Staging of rhabdomyosarcoma

Clinical group staging[2]
Group Description
I
  • Contain 13% of all cases
  • Localized region
  • Complete resection
  • No nodal involvement
II
III
IV
TNM system[3][4]
Stage Description
1
2
3
4
Risk classification[5]
Risk type Description
Low
Intermediate
High

References

  1. ↑ Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B; et al. (1990). "Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee". J Clin Oncol. 8 (3): 443–52. doi:10.1200/JCO.1990.8.3.443. PMID 2407808.
  2. ↑ Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C; et al. (1995). "The Third Intergroup Rhabdomyosarcoma Study". J Clin Oncol. 13 (3): 610–30. doi:10.1200/JCO.1995.13.3.610. PMID 7884423.
  3. ↑ Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB; et al. (2001). "Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease". J Clin Oncol. 19 (12): 3091–102. doi:10.1200/JCO.2001.19.12.3091. PMID 11408506.
  4. ↑ Dasgupta R, Fuchs J, Rodeberg D (2016). "Rhabdomyosarcoma". Semin Pediatr Surg. 25 (5): 276–283. doi:10.1053/j.sempedsurg.2016.09.011. PMID 27955730.
  5. ↑ Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ; et al. (2001). "Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V." J Pediatr Hematol Oncol. 23 (4): 215–20. PMID 11846299.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Rhabdomyosarcoma_staging&oldid=1557401"